Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Senicapoc. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 known ✓ | O15554 | 15/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.75 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KIF11 | P52732 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2337394 | 1.00 | KCNN4 (1.00) | KCNN4KCNE1KCNQ1MAPTKMT2A | |
| SCHEMBL12811863 | 0.93 | KCNN4 (0.86) | KCNN4KCNE1KCNQ1KIF11NPC1 | |
| SCHEMBL2338402 | 0.92 | KCNN4 (1.00) | KCNN4KCNE1KCNQ1MAPTKMT2A | |
| SCHEMBL812971 | 0.87 | KCNN4 (0.76) | KCNN4KCNE1KCNQ1MAPTKMT2A | |
| SCHEMBL12812145 | 0.86 | KCNN4 (1.00) | KCNN4KCNE1KCNQ1MAPTKMT2A | |
| SCHEMBL12812130 | 0.86 | KCNN4 (1.00) | KCNN4KCNE1KCNQ1MAPTKMT2A | |
| SCHEMBL1443821 | 0.86 | KCNN4 (1.00) | KCNN4KCNE1KCNQ1MAPTKMT2A | |
| SCHEMBL1443978 | 0.85 | KCNN4 (1.00) | KCNN4KCNE1KCNQ1 | |
| SCHEMBL12812142 | 0.85 | KCNN4 (1.00) | KCNN4KCNE1KCNQ1 | |
| SCHEMBL18782553 | 0.84 | KCNN4 (0.72) | KCNN4KCNE1KCNQ1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4259130-B1 | GARDOS CHANNEL INHIBITOR OR OTHER AGENTS FOR USE IN THE TREATMENT AND PREVENTION OF ANAEMIA OF INFLAMMATION | SANQUIN IP B V (NL) | 2026-03-04 | — | — | EP | claimed |
| US-12390473-B2 | Methods of treating tyrosine kinase inhibitor-induced diarrhea | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-08-19 | — | — | US | claimed |
| CN-120154730-A | Use of potassium-calcium activated channel subfamily N member 4 inhibitors for the preparation of a medicament for preventing and treating and/or delaying the progression of an abdominal aortic aneurysm disease process | 南方科技大学 | 2025-06-17 | — | — | CN | claimed |
| US-12286389-B2 | Crystalline form a of 2, 2-bis(4-fluorophenyl)-2-phenylacetamide and preparation method therefor and application thereof | Shenzhen Jingtai Technology Co., Ltd (CN) | 2025-04-29 | — | — | US | claimed |
| WO-2025032465-A1 | USE OF GARDOS CHANNEL INHIBITORS IN THE TREATMENT OF SICKLE CELL DISEASE | BIOSSIL INC. (CA) | 2025-02-13 | — | — | WO | claimed |
| US-12186286-B2 | Use of senicapoc for treatment of stroke | PARACELSUS NEUROSCIENCE LLC (US) | 2025-01-07 | — | — | US | claimed |
| WO-2024220459-A2 | COMBINATION THERAPY WITH LP-PLA2 INHIBITOR AND A SECOND AGENT | SCINEURO THERAPEUTICS INC. (US) | 2024-10-24 | — | — | WO | claimed |
| WO-2024191125-A1 | METHOD FOR ACTIVATING ENDOGENOUS NEURAL STEM CELLS THROUGH LOW-INTENSITY FOCUSED ULTRASOUND TREATMENT | 연세대학교 산학협력단 | 2024-09-19 | — | — | WO | claimed |
| US-20240050420-A1 | NANOMEDICINES FOR TREATMENT OF DISEASE | CHAPMAN UNIVERSITY | 2024-02-15 | — | — | US | claimed |
| US-20240024335-A1 | TREATMENT AND PREVENTION OF ANAEMIA OF INFLAMMATION | Sanquin IP B.V. (NL) | 2024-01-25 | — | — | US | claimed |
| US-9428568-B2 | Compositions and methods for modulating cell-cell fusion via intermediate-conductance calcium-activated potassium channels | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-30 | — | — | US | claimed |
| WO-2016134353-A1 | METHODS FOR TREATING MALARIA USING POTASSIUM CHANNEL INHIBITORS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2016-08-25 | — | — | WO | claimed |
| US-20110300152-A1 | COMPOSITIONS AND METHODS FOR MODULATING CELL-CELL FUSION VIA INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | YALE UNIVERSITY (US) | 2011-12-08 | — | — | US | claimed |
| EP-2358750-A2 | COMPOSITIONS AND METHODS FOR MODULATING CELL-CELL FUSION VIA INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | Boehringer Ingelheim International GmbH (DE) | 2011-08-24 | — | — | EP | claimed |
| US-20110124735-A1 | CARBONYLAMINO DERIVATIVES USEFUL FOR THE TREATMENT OF CERTAIN INFLAMMATORY DISORDERS | NEURO SEARCH A/S (DK) | 2011-05-26 | — | — | US | claimed |
| EP-2322164-A2 | Carbonylamino derivatives useful for the treatment of inflammatory bowel disease | NeuroSearch A/S (DK) | 2011-05-18 | — | — | EP | claimed |
| EP-2192896-A1 | CARBONYLAMINO DERIVATIVES USEFUL FOR THE TREATMENT OF CERTAIN INFLAMMATORY DISORDERS | NEUROSEARCH A/S (DK) | 2010-06-09 | — | — | EP | claimed |
| WO-2010053584-A2 | COMPOSITIONS AND METHODS FOR MODULATING CELL-CELL FUSION VIA INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-14 | — | — | WO | claimed |
| WO-2009027292-A1 | CARBONYLAMINO DERIVATIVES USEFUL FOR THE TREATMENT OF CERTAIN INFLAMMATORY DISORDERS | NEUROSEARCH A/S (DK) | 2009-03-05 | — | — | WO | claimed |
| WO-2003004010-A1 | CARBONYLAMINO DERIVATIVES USEFUL FOR OBTAINING IMMUNE REGULATION | POSEIDON PHARMACEUTICALS A/S (DK) | 2003-01-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390473-B2 | Methods of treating tyrosine kinase inhibitor-induced diarrhea | CFTR, LCK, ABL1 | KCNN4 187/4885KCNE1 268/4885KCNQ1 180/4885 |
| US-20110300152-A1 | COMPOSITIONS AND METHODS FOR MODULATING CELL-CELL FUSION VIA INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | KCNN3, KCNN4, KCNMA1 | KCNN4 2/4885KCNE1 68/4885KCNQ1 27/4885 |
| US-20110124735-A1 | CARBONYLAMINO DERIVATIVES USEFUL FOR THE TREATMENT OF CERTAIN INFLAMMATORY DISORDERS | NFKBIA, TNF, LTC4S | KCNN4 4646/4885KCNE1 4420/4885KCNQ1 3761/4885 |
| US-12286389-B2 | Crystalline form a of 2, 2-bis(4-fluorophenyl)-2-phenylacetamide and preparation method therefor and application thereof | WEE2, WEE1, WASF2 | KCNN4 3480/4885KCNE1 2963/4885KCNQ1 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.